Growth Metrics

Merck (MRK) Receivables (2016 - 2026)

Merck has reported Receivables over the past 18 years, most recently at $12.2 billion for Q1 2026.

  • Quarterly Receivables rose 13.16% to $12.2 billion in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $12.2 billion through Mar 2026, up 13.16% year-over-year, with the annual reading at $11.8 billion for FY2025, 14.57% up from the prior year.
  • Receivables was $12.2 billion for Q1 2026 at Merck, up from $11.8 billion in the prior quarter.
  • Over five years, Receivables peaked at $12.2 billion in Q1 2026 and troughed at $51.0 million in Q2 2023.
  • The 5-year median for Receivables is $10.8 billion (2025), against an average of $8.6 billion.
  • Year-over-year, Receivables plummeted 99.5% in 2023 and then surged 22727.45% in 2024.
  • A 5-year view of Receivables shows it stood at $10.0 billion in 2022, then grew by 3.9% to $10.3 billion in 2023, then decreased by 0.69% to $10.3 billion in 2024, then grew by 14.57% to $11.8 billion in 2025, then rose by 3.69% to $12.2 billion in 2026.
  • Per Business Quant, the three most recent readings for MRK's Receivables are $12.2 billion (Q1 2026), $11.8 billion (Q4 2025), and $12.1 billion (Q3 2025).